Search
for
Sort by
Research 61–90 of 388
- Cutaneous Side Effects of Chemotherapy and Radiotherapy
- Alopecia areata: from immunopathogenesis to emerging therapeutic approaches
- Clinical Outcomes of Ritlecitinib in Treatment-Refractory Alopecia Areata: A Single-Center Real-World Study
- Systemic Treatment of Moderate to Severe Alopecia Areata in Adults: Updated Australian Expert Consensus Statement
- JAK 1-3 inhibitors and TYK-2 inhibitors in dermatology: Practical pearls for the primary care physician
- Inhibition of T-cell activity in alopecia areata: recent developments and new directions
- Treatment Patterns and Unmet Needs in the Management of Alopecia Areata: Results of a Physician’s Survey in the Middle East
- Overview of alopecia areata for managed care and payer stakeholders in the United States
- Hair regrowth in a patient with alopecia universalis and psoriasis vulgaris during deucravacitinib therapy
- Assessing Alopecia Areata Management in Poland: Challenges in Medical Practices and Patient Care
- “<i>Nomen Omen</i>: The Myth of God Janus”
- From mechanisms to therapies: current advances breakthroughs in alopecia areata immunopathology
- Alopecia Areata in Skin of Color Patients: New Considerations Sparked by the Approval of Baricitinib
- The Possible Role of Antibodies in Alopecia: A Narrative Review
- JAK-Inhibitors Beyond the Label: Emerging Applications in Dermatology
- Which is the ideal JAK inhibitor for alopecia areata – Baricitinib, tofacitinib, ritlecitinib or ifidancitinib - Revisiting the immunomechanisms of the JAK pathway
- Emerging Topical and Systemic JAK Inhibitors in Dermatology
- Treatments for Moderate-to-Severe Alopecia Areata: A Systematic Narrative Review
- Repigmentation Competence in Vitiligo: Integrating Immune, Regulatory, Regenerative, and Microenvironmental Axes
- Chemotherapy-Induced Alopecia Beyond Cytotoxicity: Hair Follicle Immune Privilege Collapse and JAK-STAT Signaling
- Evaluating Current and Emergent JAK Inhibitors for Alopecia Areata: A Narrative Review
- Considerations for the Treatment Strategy of Relapse After Tofacitinib Therapy in Alopecia Areata
- INIBIDORES DA JANUS QUINASE PARA O TRATAMENTO DA ALOPECIA AREATA
- Comprehensive Safety Exposure‐Response Analysis to Support Ritlecitinib Dose Selection
- Alopecia Areata: Pathogenesis, current treatments, and future perspectives
- Efficacy and Tolerability of Brevilin-A, a Natural JAK Inhibitor, in Pediatric Alopecia Areata: A Case Series
- II Consensus of the Brazilian Society of Dermatology for the treatment of alopecia areata
- Dermal T cell immunity and key regulatory signaling pathways: Implications in immune-mediated alopecia and hair regeneration
- 42004 Scalp, eyebrow, and eyelash hair regrowth with continued ritlecitinib treatment among patients with alopecia areata without target efficacy response at Week 24: post hoc analysis of the ALLEGRO phase 2b/3 study
- Assessing Alopecia Areata Management in Poland: Challenges in Medical Practices and Patient Care